Trial Name: DO410
A National Web-Based Randomized Phase III Study of Erlotinib or Placebo Following Concurrent Docetaxel, Carboplatin and Thoracic Radiotherapy in Patients with Inoperable Stage III Non-Small Cell Lung Cancer
Trial Description:
The objective of this trial is to determine whether taking erlotinib (Tarceva) following treatment with chemotherapy and radiation therapy for inoperable stage III, non-small cell lung cancer is more effective than chemotherapy and radiation therapy alone.
Treatment Plan:
Patients will be randomized to one of two treatment arms:
1. Arm A - chemotherapy, radiation therapy plus tarceva
2. Arm B - chemotherapy, radiation therapy plus placebo
Patients:
- Newly diagnosed inoperable Stage III non-small cell lung cancer with no evidence of metastatic disease
- No brain metastases
- No previous chemotherapy or radiation therapy for lung cancer
- Lab tests, a current physical exam and medical history must meet study specific criteria
This is a brief overview of this clinical trial and only selected eligibility criteria are listed.
If you are interested in receiving more information to see if you are eligible to participate in this study, please contact:
Mercy General Hospital, Rhoda Pineda at (916) 453-4651, or e-mail rpineda@chw.edu
Mercy San Juan Medical Center, Margaret Murphy at (916) 537-5109, or e-mail margaret.murphy2@chw.edu
